Health CarePharmaceuticals & Biotechnology
  • Price (DKK)290.30
  • Today's Change-3.20 / -1.09%
  • Shares traded655.83k
  • 1 Year change-17.01%
  • Beta1.1186
Data delayed at least 15 minutes, as of Sep 20 2019 15:59 BST.
More ▼

Profile data is unavailable for this security.

About the company

Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America. It develops and distributes solutions within the market areas agriculture, bioenergy, food & beverages, household care, leather, pharmaceuticals, forest products, textile and wastewater solutions. Novozymes operates through a range of partnerships with companies, such as Adisseo, Beta Renewables, DONG Energy and Monsanto, and is a parent company of Novozymes Belgium BVBA, Novozymes BioAg Limited, Novozymes Canada Limited, Albumedix A/S and Organobalance GmbH, among others.

  • Revenue in DKK (TTM)14.31bn
  • Net income in DKK3.24bn
  • Incorporated2000
  • Employees6.46k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Clariant AG37.21bn-20.43m45.33bn17.79k--2.6820.541.22-0.0090.08216.577.470.68514.445.98305,178.500.15053.340.21364.8429.7129.940.21974.350.8747--0.471261.943.861.7445.262.49-4.238.85
Arkema SA66.03bn4.41bn48.61bn20.00k11.031.285.620.73627.707.70115.4766.450.87715.746.30441,929.
Johnson Matthey PLC91.02bn3.50bn51.23bn12.99k14.582.3210.360.56292.142.1455.7613.491.958.697.52827,302.107.498.0911.1011.479.468.083.843.431.0012.840.334356.154.58-0.746538.593.957.095.26
Uralkaliy PAO20.11bn4.83bn51.71bn20.50k3.291.427.762.5736.2036.20148.5783.760.36215.068.36--8.714.7212.556.3175.5275.8924.0515.210.4072--0.75170.007.8810.40-117.49--10.58--
Brenntag AG95.55bn3.49bn53.62bn16.98k15.352.2110.270.56123.033.0382.9821.011.598.316.46770,125.205.815.508.367.6120.9821.303.663.431.188.040.444640.276.875.1427.746.3212.686.73
Novozymes A/S14.31bn3.24bn70.54bn6.46k26.587.7716.064.9311.1911.1949.4138.280.73552.265.252,334,203.0016.6516.1422.6920.5356.2957.8622.6321.210.752721.780.296740.24-0.97034.143.437.9612.1114.87
Chr Hansen Holding A/S8.60bn1.83bn74.21bn3.15k40.5011.8632.138.6313.9013.9065.1947.470.60243.146.612,728,721.0012.8511.7115.4813.8555.8053.3921.3319.700.806316.040.491373.713.288.251.8810.618.7314.69
Evonik Industries AG105.04bn5.45bn80.03bn35.81k14.681.456.500.76191.571.7230.1915.820.68324.617.79390,311.603.664.494.475.4829.2231.105.355.911.108.600.389865.644.463.4130.438.24-0.96012.83
Yara International ASA89.48bn3.91bn82.49bn16.76k21.111.388.640.921919.0519.05435.40291.560.7663.997.507,090,
Data as of Sep 20 2019. Currency figures normalised to Novozymes A/S's reporting currency: Danish Krone DKK

Institutional shareholders

17.96%Per cent of shares held by top holders
HolderShares% Held
Baillie Gifford & Co.as of 31 Dec 201712.56m5.30%
The Vanguard Group, Inc.as of 31 Jul 20195.79m2.44%
Invesco Advisers, Inc.as of 30 Jun 20194.44m1.87%
Putnam Investment Management LLCas of 31 Mar 20193.59m1.51%
MFS International (UK) Ltd.as of 31 Jul 20193.11m1.31%
Harding Loevner LPas of 31 Jul 20193.11m1.31%
Norges Bank Investment Managementas of 31 Dec 20183.10m1.31%
BlackRock Fund Advisorsas of 05 Sep 20192.64m1.11%
Walter Scott & Partners Ltd.as of 30 Jun 20192.15m0.91%
NNIP Advisors BVas of 31 Mar 20192.13m0.90%
More ▼
Data from 31 Dec 2018 - 30 Aug 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.